Pharma Mar SA (PHM) – Company Profile and SWOT Analysis
- Pages: 52
- Published: August 2024
- Report Code: MLPH140326FSA
Pharma Mar SA (PHM) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company. It discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin), an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. It also develops RNAi candidates for the treatment of retina diseases. The company operates through its subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the US. Pharma Mar is headquartered in Colmenar Viejo, Madrid, Spain.
Scope
• Detailed information on Pharma Mar SA required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Pharma Mar SA in the form of a SWOT analysis
• An in-depth view of the business model of Pharma Mar SA including a breakdown and examination of key business segments
• News about Pharma Mar SA, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of Pharma Mar SA and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess Pharma Mar SA as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on Pharma Mar SAs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
CTI BioPharma Corp
Ariad Pharmaceuticals (Spain) SL
GP Pharm SA
Ability Pharmaceuticals SL
Oryzon Genomics SA
Traslational Cancer Drugs Pharma SL
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.